Abstract

Mentara Therapeutics Launches to Advance MTA-304 for Levodopa-Induced Dyskinesia in Parkinson’s Disease

October 7, 2026

7 October 2026 SPRIM Global Investments-backed Mentara Therapeutics has launched following its acquisition of the investigational drug EM-221, now called MTA-304, from EuMentis Therapeutics. The…

Latest News

Mentara Therapeutics Launches to Advance MTA-304 for Levodopa-Induced Dyskinesia in Parkinson’s Disease

October 7, 2026

Body Vision Medical Closes New Funding Round to Accelerate Global Expansion of AI-Powered Intraoperative Imaging

August 18, 2026

R&D SERVICES/CRO

Inside the NHS Hospital Trialling Psychedelics to Treat Depression

July 8, 2026

EBT Medical and NinaMED Announce US$13.75M Financing to Advance Licensed NiNA System® for Overactive Bladder

May 15, 2026

Logan Voss 78qfdy9e9me Unsplash

Hope for Dry AMD: Novel Gene Therapy Completes First Human Safety Trial

April 29, 2026

Obviogo Oraclelifesciences Clinicalone Integration

DIGITAL CLINICAL SOLUTION

ObvioGo Now Integrated with Oracle Life Sciences Clinical One Data Collection

February 11, 2026

Pulsesight Pst 611 Phasei Dosingcompleted Dryamd Ga

Dosing completed in the Phase I clinical trial of PulseSight Therapeutics’ PST-611 treatment for dry AMD/Geographic Atrophy (GA)

January 22, 2026

Ervimmune E17m Seriesa Clinicaldevelopment Cancervaccine

ErVimmune raises €17 million in Series A first closing to enter clinical development with lead cancer vaccine candidate

January 21, 2026

Kahr Cancer Immunotherapy Financing News

KAHR Bio Announces Strong Topline Phase 2 Results for DSP107 in Combination with Anti-PD-L1 Therapy in Colorectal Cancer

January 9, 2026

Lattice Medical Raises 43m Post Cancer Reconstruction

Lattice Medical raises €43 million to transform post-cancer reconstruction

October 29, 2025

Treos Bio Phase Ii Clinical Trial Mss Colorectal Cancer

TREOS Bio Partners with Charité Berlin and Junshi Biosciences to Launch Pivotal Phase II Clinical Trial in Refractory MSS Colorectal Cancer

August 27, 2025

Vaxxas Hd Map A90m Funding

Vaxxas secures ~A$90 million in funding to commercialise needle-free vaccination delivery technology

August 25, 2025

Doron Therapeutics Positive Phase 2 End Of Phase Meeting 2025

Doron Therapeutics Announces Positive End-of-Phase 2 and Initial RMAT Meeting With FDA for MOTYS (PTP-001) in the Treatment of Knee Osteoarthritis

May 20, 2025

Azalea Vision 9m Series A Intelligent Connected Vision Platform

Azalea Vision Raises €9 Million in First Closing of Series A to Further Develop Intelligent Connected Vision Platform

April 30, 2025

Cadwell Seer Investment Epilepsy Diagnostics 2025

Cadwell Makes a Strategic Investment in Seer Medical to Expand Home-Based Epilepsy Diagnostics

April 16, 2025

Sprim Oneim 300m Joint Venture Clinical Trial Financing 2025

R&D SERVICES/CRO

SPRIM Global Investments and OneIM Announce $300mn Joint Venture to Accelerate Clinical Trial Financing

March 11, 2025

Pulsesight Series A Financing Pst 611 Dry Amd 2025 1

PulseSight Therapeutics Announces First Close of its Series A Financing to Fund Clinical Development of PST-611 in dry AMD

February 13, 2025

Obviohealth Obviogo 2.2 Ai Driven Study Management 2025

DIGITAL CLINICAL SOLUTION

ObvioHealth Introduces ObvioGo 2.2: Transforming Study Management with AI-Driven Innovation

January 17, 2025

Rheumagen Series A Financing Hla Gene Editing Therapies 2024 1

RheumaGen, Inc. Launches with $15 Million Series A Financing to Advance a New Class of HLA Gene-Editing Therapies for Major Autoimmune Diseases

January 9, 2025

Cilcare Completes 40m Series A

Cilcare completes a €40M series A

December 5, 2024

Doron Therapeutics 11m Series A Osteoporosis Drug Phase 3 Clinical Study

Doron Therapeutics Raises $11M Series A to Progress Biologic Regenerative Osteoarthritis Drug into Phase 3 Clinical Studies

November 25, 2024

Napo Therapeutics Best Pharmaceuticals Innovator Europe 2024

Jaguar Health Family Company Napo Therapeutics Named “Best Pharmaceuticals Innovator of the Year – Europe”

November 19, 2024

Obviohealth Richard Watkins Chief Revenue Officer Transformation

ObvioHealth Welcomes Richard Watkins as Chief Revenue Officer at a Pivotal Moment of Transformation

October 16, 2024

Obviohealth Appointment Nicholas Campbell 2024

DIGITAL CLINICAL SOLUTION

ObvioHealth Announces the Appointment of Nicholas Campbell to Its Board of Directors

October 10, 2024

Pulsesight Therapeutics Presents Pst 611 Ever Congress 2024

PulseSight Therapeutics to Present Data on PST-611 at EVER Congress 2024

October 7, 2024

Novel Validated Approach Monitoring Infant Growth Home Clinical Trials

R&D SERVICES/CRO

SPRIM PRO Announces a Novel and Validated Approach for Monitoring Infant Growth from Home in Clinical Trials, Reducing Burdens on Caregivers and Clinical Sites

September 24, 2024

Obviohealth Strategic Investment By Guardant Health

DIGITAL CLINICAL SOLUTION

ObvioHealth announces strategic investment by Guardant Health to accelerate deployment of oncology clinical trials globally

July 29, 2024

Mimi Tang Prota Therapeutics Forbes Australia

Forbes Australia recognizes Prota Therapeutics for making waves in Australia’s startup scene at the moment

June 24, 2024

Biosenic On Its Way To Find The Necessary Funds To Perform Its Key Clinical Trial On Chronic Graft Versus Host Disease

Prota Therapeutics US $21 Million Financing Led by SPRIM Global Investments

January 16, 2024

Spexis Provides Update Regarding Debt Restructuring Moratorium

Stalicla Secures $17.4 Million in Series B Financing

January 16, 2024

This site uses cookies to offer you a better browsing experience. By browsing this website, you agree to our use of cookies.

Accept